VTGN News and Press, VistaGen Therapeutics Inc. From 05/31/22

3 Penny Stocks to Add to Your Watchlist This Month With another day of trading penny stocks over, there is a lot to be excited about. Over the past week, we have seen some major stock market movements. While this can lead to large losses, it can also lead to very sizable gains. To under...

VistaGen Therapeutics (NASDAQ: VTGN ), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, will present at two upcoming conf...

VistaGen will present at upcoming William Blair 42 nd Annual Growth Stock Conference and Jefferies Global Healthcare Conference VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to tra...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ...

VistaGen Therapeutics (NASDAQ:VTGN) on Thursday said the U.S. Food and Drug Administration (FDA) agreed that the company's nasal spray PH94B for the acute treatment of social anxiety disorder (SAD) did not show any abuse potential. The FDA agreed that data from nonclinical and clinical studie...

VistaGen Therapeutics (NASDAQ: VTGN ), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, has announced its new chief legal...

VistaGen Therapeutics (NASDAQ: VTGN ), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, will be presenting its research a...

Research presented at the Annual Meeting of the Society of Biological Psychiatry and of the American Society of Clinical Psychopharmacology highlight fundamentally differentiated mechanism of action for PH94B These preclinical data demonstrate that intranasal radiolabelled...

VectorBuilder announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou. Bayer announced China approval of Vitrakvi™ (larotrectinib), a precision medicine for adult and pediatric patients who have advanced solid tumors that harbor a Ne...

VistaGen Therapeutics (NASDAQ:VTGN) and AffaMed Therapeutics said they have completed regulatory preparations to begin a phase 3 trial of VistaGen’s nasal spray PH94B (AM005) for the acute treatment of anxiety in adults with social anxiety disorder (SAD), in the U.S. and China. Th...